Abstract:In Oncology, trials evaluating drug combinations are becoming more common. While combination therapies bring the potential for greater efficacy, they also create unique challenges for ensuring drug safety. In Phase-I dose escalation trials of drug combinations, model-based approaches enable efficient use of information gathered, but the models need to account for trial complexities: appropriate modeling of interactions becomes increasingly important with growing numbers of drugs being tested simultaneously in a given trial. In principle, we can use data from multiple arms testing varying combinations to jointly estimate toxicity of the drug combinations. However, such efforts have highlighted limitations when modelling drug-drug interactions in the Bayesian Logistic Regression Model (BLRM) framework used to ensure patient safety. Previous models either do not account for non-monotonicity due to antagonistic toxicity, or exhibit the fundamental flaw of exponentially overpowering the contributions of the individual drugs in the dose-response. This specifically leads to issues when drug combinations exhibit antagonistic toxicity, in which case the toxicity probability gets vanishingly small as doses get very large. We put forward additional constraints inspired by Paracelsus' intuition of "the dose makes the poison" which avoid this flaw and present an improved interaction model which is compatible with these constraints. We create instructive data scenarios that showcase the improved behavior of this more constrained drug-drug interaction model in terms of preventing further dosing at overly toxic dose combinations and more sensible dose-finding under antagonistic drug toxicity. This model is now available in the open-source OncoBayes2 R package that implements the BLRM framework for an arbitrary number of drugs and trial arms.

A Markov Chain Monte-Carlo Approach to Dose-Response Optimization Using Probabilistic Programming (RStan)

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors

A Bayesian latent-subgroup platform design for dose optimization

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

Dose Selection Balancing Efficacy and Toxicity Using Bayesian Model Averaging

Improving the Performance of Bayesian Logistic Regression Model with Overdose Control in Oncology Dose-Finding Studies

Quantitative Risk Assessment: Developing a Bayesian Approach to Dichotomous Dose-Response Uncertainty

Bayesian Nonparametric Risk Assessment in Developmental Toxicity Studies with Ordinal Responses

Markov models for clinical decision‐making in radiation oncology: A systematic review

Fitting Bayesian item response models in Stata and Stan

A Novel Approach to Optimize Combinatory Drugs Using Markov Chain.

A Robust Proposal for Heteroscedastic Dose–Response Models with an Application to Interaction Analysis

Convex Mixture Regression for Quantitative Risk Assessment

Benchmark Dose Analysis via Nonparametric Regression Modeling

MetaStan: An R package for Bayesian (model-based) meta-analysis using Stan

Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I

Principled Drug-Drug Interaction Terms for Bayesian Logistic Regression Models of Drug Safety in Oncology Phase I Combination Trials

DOD-BART: machine learning-based dose optimization design incorporating patient-level prognostic factors via Bayesian additive regression trees

Bayesian Model-Averaged Benchmark Dose Analysis Via Reparameterized Quantal-Response Models

Response-adaptive dose-finding under model uncertainty